Table 2. Clinical activity of... | American Society of Hematology

Table 2.

Clinical activity of blinatumomab and inotuzumab ozogamicin in relapsed/refractory ALL

Parameter	Blinatumomab				Inotuzumab ozogamicin
	Ph⁺ ALL phase 2	Ph^– ALL			Single dose	Weekly dose	Weekly dose	INO-VATE phase 3 trial	Inotuzumab + mini-HCVD
	Ph⁺ ALL phase 2	Pivotal phase 2	Confirmatory phase 2	TOWER phase 3 trial	Single dose	Weekly dose	Weekly dose	INO-VATE phase 3 trial	Inotuzumab + mini-HCVD
No. of patients	45	36	189	271	49	41	35	109	52
ORR, %	36	69	43	45	57	59	66	81	77
Median OS, mo	7.1	9.8	6.1	7.7	5	7.3	7.4	7.7	11

Parameter	Blinatumomab				Inotuzumab ozogamicin
	Ph⁺ ALL phase 2	Ph^– ALL			Single dose	Weekly dose	Weekly dose	INO-VATE phase 3 trial	Inotuzumab + mini-HCVD
	Ph⁺ ALL phase 2	Pivotal phase 2	Confirmatory phase 2	TOWER phase 3 trial	Single dose	Weekly dose	Weekly dose	INO-VATE phase 3 trial	Inotuzumab + mini-HCVD
No. of patients	45	36	189	271	49	41	35	109	52
ORR, %	36	69	43	45	57	59	66	81	77
Median OS, mo	7.1	9.8	6.1	7.7	5	7.3	7.4	7.7	11

mini-HCVD, mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone; ORR, objective response rate; OS, overall survival.